WTA
VRTX icon

Washington Trust Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Washington Trust Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$168K Sell
377
-106
-22% -$49.4K 0.01% 239
2025
Q4 		$219K Buy
483
+134
+38% +$57.8K 0.02% 217
2025
Q3 		$137K Buy
349
+26
+8% +$10.9K 0.01% 252
2025
Q2 		$144K Buy
323
+25
+8% +$11.5K 0.01% 227
2025
Q1 		$144K Buy
298
+59
+25% +$27.5K 0.01% 220
2024
Q4 		$96.2K Sell
239
-69
-22% -$32K 0.01% 261
2024
Q3 		$143K Sell
308
-5
-2% -$2.4K 0.01% 229
2024
Q2 		$147K Sell
313
-63
-17% -$27.3K 0.01% 219
2024
Q1 		$157K Sell
376
-161
-30% -$68.1K 0.01% 212
2023
Q4 		$218K Sell
537
-33
-6% -$12.2K 0.02% 186
2023
Q3 		$198K Sell
570
-6
-1% -$2.1K 0.02% 186
2023
Q2 		$203K Sell
576
-128
-18% -$43.1K 0.02% 181
2023
Q1 		$222K Buy
704
+54
+8% +$16.2K 0.02% 171
2022
Q4 		$188K Sell
650
-1,575
-71% -$480K 0.02% 187
2022
Q3 		$644K Sell
2,225
-165
-7% -$47.5K 0.06% 123
2022
Q2 		$673K Sell
2,390
-637
-21% -$170K 0.06% 118
2022
Q1 		$790K Sell
3,027
-552
-15% -$131K 0.06% 123
2021
Q4 		$786K Buy
+3,579
New +$696K 0.05% 131

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Washington Trust Advisors's VRTX Position: Q1 2026 in Review

Washington Trust Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q1 2026, selling an estimated $49.4K and leaving 377 shares worth $168K. The position accounts for 0.01% of the portfolio, ranked #239.

Washington Trust Advisors first reported a position in VRTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $790K in Q1 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Washington Trust Advisors held 377 shares of Vertex Pharmaceuticals worth $168K as of Q1 2026.
  • Washington Trust Advisors sold 106 Vertex Pharmaceuticals shares in Q1 2026, an estimated $49.4K.
  • Vertex Pharmaceuticals made up 0.01% of Washington Trust Advisors's portfolio in Q1 2026, its #239 holding.
  • Washington Trust Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Washington Trust Advisors's Vertex Pharmaceuticals position peaked at $790K in Q1 2022.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Washington Trust Advisors's 13F filing for Q1 2026, filed 6 Apr 2026.